We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Robotic Tech | RTS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.25 | 3.25 |
| Top Posts |
|---|
Posted at 13/7/2012 19:44 by pentangle Not sure if anyone else did not sell out. However, the Robotic Legacy company, which holds the legacy assets including the loan notes, paid out a divi of £210 a share today. |
Posted at 18/3/2011 10:24 by envirovision Whats to say, its all moving in the right direction so as existing shareholders get slowly wiped out and left with nothing just as we predicted.In particular like this: The Company also does not possess sufficient distributable reserves to pay a substantial dividend. To translate this coupled with the savings on the de-listing: "Although we extended to loan notes to 2014, they still look worthless and we expect this situation not to change. However in order for us to find out for sure, we are undertaking this plan so as to be able to maximise and pay ourselves our salary for the next 4 years to find out" |
Posted at 13/1/2011 08:28 by chrisdgb Well I am back in here this morning, used to hold RTS.Crazy price now given the cash and tax losses... Let us hope the shrewd IAV can get a decent acquistion... Could well be a long term multi bagger... I suppose we need a new thread as well.. |
Posted at 11/1/2011 15:39 by pentangle If they all sat around and did nothing, the payout should be 7p a share, assuming the loan notes which make up about half of this get paid by Doerfer (a US company which RTS sold a subsidiary to and who gave loan notes in part payment).The problem is that the Directors have threatened to use their 'expertise' to invest the money in other companies which opens the very real possibility that they will fritter the money away. So, no, its not fair to say there is no chance of shareholder value. There is every chance, but there is a risk. |
Posted at 08/12/2010 13:28 by nailsaz pentangle,I did a bit of research into the court case after the Supreme court ruling (i actually trained as a lawyer originally). The whole process seemed to be a bit of a vanity exercise for RTS. I think the original contract was around £1.7m in 2005 but you have to dig into the fine print to see that Muller actually paid 70% of this in 3 payments and the legal proceedings were over the final payment of a little over 500k. This is a sizeable amount but from looking at RTS's annual statements since 2005 I can see approximately £1.5 million in legal costs spent on recovering this. Im not 100% sure if all these costs were cash flows or simply balance sheet provisions (which has huge impact on the actual costs recoverable from Muller). I would imagine Muller will have to pay the 30% of contract and reasonable costs. This would seem more certain in my view than the Doerfer loan notes but im not sure why it has taken since March to hear news. |
Posted at 07/12/2010 13:25 by pentangle NailsazIn the disposal document it referred to the following assets: Cash - £2.0m or 3.2p a share Loan Notes - £2.3m or 3.65p per share (plus interest of $1m to 2014 or 1.0p per share) R&D Tax Credits - up to £250k or .4p a share Legal Dispute - unknown, possible recovery of costs and payment due to Flexible Systems? Thus if the loan notes perform, and we assume nothing from the tax credits and the legal battle that gives us 7.85p per share. The rest is upside. What really worries me is the implied threat also contained in the disposal document ie 'The Company will draw on the deep expertise of the Directors in engineering and industrial technology in order to differentiate it from pure financial investors, but will benefit from the application of the same financial disciplines.' These guys have do not have the greatest record at RTS (or HEP as I guess we should get used to calling it), and I imagine they are quite capable of frittering away this shareholder value. So the jury is out, though I obviously hope they succeed. BTW Doerfer are a large private US company, hence no figures available, but who have clearly struggled to pay these loan notes. Therefore getting them paid is not a given. |
Posted at 10/3/2010 20:46 by zedder Have to say the spread stinks with RTS. Might go with MIRL instead. |
Posted at 21/1/2010 08:00 by chrisdgb Article from the Manchester Business News:Investors raise stake in Robotic Technology Systems A Jersey-registered company has increased its stake in Robotic Technology Systems Plc (AIM: RTS), the Salford-based maker of automated handling systems for the food and life science sectors. Industrial Acquisition Vehicle Ltd, which is backed by London-based investors, made an abortive takeover approach for RTS last year. The two sides were unable to agree terms but IAV said it wanted to remain involved with the company and put one of its directors on the board. Today RTS announced that IAV bought another 2.63 million shares on November 26 last year, taking its holding to 17.9 million or 28.73 per cent. |
Posted at 07/1/2010 15:31 by chrisdgb this is the sort of thing in the life sciences division:RTS Life Science Launches Tube Auditor with Unique Vision Technology 04/12/2009 Manchester, UK (December 4, 2009) RTS Life Science, a worldwide supplier of automated sample management and drug delivery testing systems announces the launch of its innovative Tube Auditor instrument. With units already on order from 3 of the top 10 pharma and a major US Biobank, the Tube Auditor features unique vision technology, (patent pending*) allowing for fast and accurate volume measurement of samples, and is targeted at the Compound Management, High Throughput Screening and Bio-banking marketplace. RTS Life Science will unveil this new instrument on booth #644 at LabAutomation, which will take place at the Palm Springs Convention Center, Palm Springs, CA from January 23-27, 2010. The RTS Tube Auditor is a bench-top instrument suitable for manual operation or integration into automated systems. It enables fast and accurate measurement of sample volumes and, uniquely, the detection of precipitate in sample tubes. Its high speed vision technology allows a full 96-way SBS tube rack to be audited in less than 2 minutes. Unlike other automated solutions, the RTS Tube Auditor ensures complete sample safety and avoids the potential for sample degradation as there is no need to de-cap tubes during the auditing process. During LabAutomation 2010, RTS Life Science will be hosting a workshop in collaboration with Microsonics Systems. The workshop, entitled "See and Hear how Vision and Acoustic Technology Could save $$$ in Your Screening and Library Collection," will highlight how two complementary technologies can minimise poor quality screening and improve results by finding and then correcting solubility issues within compound libraries. With a focus on the new Tube Auditor and its innovative vision technology, and how Microsonics use ultrasonic energy to re-solubilise compounds, this workshop is sure to be of great interest. The workshop will take place on Tuesday, January 26, 2010 at 12:30 2:00p.m in the Convention Center, room Smoketree DE. To register, click here. In addition, RTS Life Science will present two new posters at LabAutomation 2010. One of these posters, entitled "Improving Screening Results Using Vision Technology", will demonstrate the many benefits of using RTS vision technology to routinely and accurately audit sample tubes. These benefits include minimising costs from wasted screening of empty plate wells, and avoiding screening samples at the wrong concentration by early detection of precipitated samples. A competition will also take place on the booth where visitors will be able to estimate the volume of sample in a tube with the closest standing the chance to win an iPod touch. With 25 years of experience delivering automation solutions, RTS Life Science is a major supplier of large scale sample storage and testing within the laboratory environment. To learn more about RTS Life Science's revolutionary Tube Auditor or to enter the competition, please visit booth #644 at LabAutomation 2010. |
Posted at 15/9/2009 14:12 by slj RTS has money in the bio-bankJames Ferguson September 15, 2009 A COMPANY'S push into the fast-growing life sciences sector is helping to put it on course for profit. Robotic Technology Systems, which earlier this month announced talks over a possible takeover had collapsed, is making strong sales of equipment to pharmaceutical companies across the globe, from the United States to Israel. The life sciences division at RTS, which is based at Irlam, has a healthy £4.7m order book and analysts believe this will fuel the firm's surge into the black. Michael Campbell, of Collins Stewart, is forecasting earnings of £200,000 for RTS this year, against losses of £1.1m and £1.5m in 2008 and 2007 respectively. In addition to its success overseas, the life sciences division is making an impact closer to home. This month marks 25 years since the discovery of DNA profiling, and RTS is helping in the fight against disease by equipping the world's biggest DNA database. From an unassuming warehouse on an Irlam industrial estate to the west of Manchester, its experts have provided the equipment that powers the UK Biobank in Stockport - the largest of its type in the world. The three-year project will see DNA samples taken from 500,000 people with the aim of tackling genetic illnesses including cancer, heart disease, diabetes, arthritis and dementia. Gary Walsh, managing director of the life sciences division, said: "Biobanking is a new market for us, working with government and academic research institutions. "The UK Biobank is the leading project in the world and we have already developed second generation equipment for similar schemes in Europe." RTS technology also enables pharmaceutical giants to quickly and accurately access the industry's `crown jewels' - storage facilities containing 57m different chemical compounds, each of which holds the potential to treat or cure a disease or condition. Audited These chemicals must be precisely measured and audited before being stored under specific conditions - commonly at temperatures of minus 20C - and must be instantly accessible by scientists. RTS supplies the software and hardware, as well as installation, training and maintenance. It has registered 12 patents for its innovations. While the company, which employs 110 staff, has been through some tough times - it sold its nuclear engineering business in 2006 after expansion plans failed to achieve expected results - its focus on the life science markets is bearing fruit. Mr Walsh said: "Our order book is up, our turnover is up and we are recruiting. "We have a great relationship with eight of the big 10 pharmaceutical companies and we have the capacity to offer integrated systems rather than particular products. "Our staff are high calibre, highly technically competent and a real asset of the company. They are incredibly important to what we deliver." Research and development is a crucial part of the RTS, which invests five per cent of its turnover in developing new products. Another emerging market for the life sciences division is automated drug delivery testing, which includes equipment to test an asthma inhaler hundreds of times to ensure it is supplying the right drug dose throughout its lifespan. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
